Drug innovation will spur Pfizer’s dividend

PFIZER INC. $42 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.8 billion; Market cap: $243.6 billion; Dividend yield: 3.4%; Dividend Sustainability Rating: Highest; www.pfizer.com) is one of the world’s leading prescription drugmakers. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia)… Read More

Spinoff plans enhance their prospects

GENERAL ELECTRIC CO. $8.98 (New York symbol GE, Manufacturing & Industry sector; Shares outstanding: 8.7 billion; Market cap: $78.1 billion; Dividend yield: 0.5%; Takeover Target Rating: Medium; www.ge.com) recently announced a major restructuring that will narrow its focus to three main businesses: aviation operations (jet engines and aircraft… Read More

Our top ETF for 2019

SPDR S&P 500 ETF $258 (New York symbol SPY) holds the stocks in the S&P 500 Index; they are 500 major U.S. companies chosen based on their market cap, liquidity and industry group.
The highest-weighted stocks for the SPDR S&P 500 ETF are Microsoft, 3.8%; Apple, 3.4%; Amazon.com,… Read More

Dividend Advisor Hotline – Friday, January 4, 2019

PFIZER INC., $43.00, New York symbol PFE, is one of the world’s largest makers of prescription drugs. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia) and Enbrel (rheumatoid arthritis).

Starting with the March 2019 payment, Pfizer will increase its quarterly dividend by 5.9%,… Read More

Five North American ETF buys and one sell

The six ETFs we update below mainly hold high-quality stocks that are widely traded on Canadian and U.S. exchanges. Each fund tracks the performance of a major stock market index. That’s different from ETFs focused on narrower indexes or themes such as cryptocurrencies or biotechnology.
Of… Read More